FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2974058425> ?p ?o ?g. }

• W2974058425 endingPage "1167" @default.
• W2974058425 startingPage "1167" @default.
• W2974058425 abstract "Before 2016, safety concerns limited metformin use in patients with kidney disease; however, the effectiveness of metformin on clinical outcomes in patients with reduced kidney function remains unknown.To compare major adverse cardiovascular events (MACE) among patients with diabetes and reduced kidney function who continued treatment with metformin or a sulfonylurea.Retrospective cohort study of US veterans receiving care within the national Veterans Health Administration, with data supplemented by linkage to Medicare, Medicaid, and National Death Index data from 2001 through 2016. There were 174 882 persistent new users of metformin and sulfonylureas who reached a reduced kidney function threshold (estimated glomerular filtration rate <60 mL/min/1.73 m2 or creatinine ≥1.4 mg/dL for women or ≥1.5 mg/dL for men). Patients were followed up from reduced kidney function threshold until MACE, treatment change, loss to follow-up, death, or study end (December 2016).New users of metformin or sulfonylurea monotherapy who continued treatment with their glucose-lowering medication after reaching reduced kidney function.MACE included hospitalization for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death. The analyses used propensity score weighting to compare the cause-specific hazard of MACE between treatments and estimate cumulative risk accounting for the competing risks of changing therapy or noncardiovascular death.There were 67 749 metformin and 28 976 sulfonylurea persistent monotherapy users; the weighted cohort included 24 679 metformin and 24 799 sulfonylurea users (median age, 70 years [interquartile range {IQR}, 62.8-77.8]; 48 497 men [98%]; and 40 476 white individuals [82%], with median estimated glomerular filtration rate of 55.8 mL/min/1.73 m2 [IQR, 51.6-58.2] and hemoglobin A1c level of 6.6% [IQR, 6.1%-7.2%] at cohort entry). During follow-up (median, 1.0 year for metformin vs 1.2 years for sulfonylurea), there were 1048 MACE outcomes (23.0 per 1000 person-years) among metformin users and 1394 events (29.2 per 1000 person-years) among sulfonylurea users. The cause-specific adjusted hazard ratio of MACE for metformin was 0.80 (95% CI, 0.75-0.86) compared with sulfonylureas, yielding an adjusted rate difference of 5.8 (95% CI, 4.1-7.3) fewer events per 1000 person-years of metformin use compared with sulfonylurea use.Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE." @default.
• W2974058425 created "2019-09-26" @default.
• W2974058425 creator A5000770289 @default.
• W2974058425 creator A5016472568 @default.
• W2974058425 creator A5020436097 @default.
• W2974058425 creator A5032249344 @default.
• W2974058425 creator A5048334353 @default.
• W2974058425 creator A5057987348 @default.
• W2974058425 creator A5063398179 @default.
• W2974058425 creator A5086894012 @default.
• W2974058425 creator A5089308976 @default.
• W2974058425 date "2019-09-24" @default.
• W2974058425 modified "2023-09-25" @default.
• W2974058425 title "Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function" @default.
• W2974058425 cites W1526927233 @default.
• W2974058425 cites W1966714873 @default.
• W2974058425 cites W1972033537 @default.
• W2974058425 cites W1981055539 @default.
• W2974058425 cites W1986628483 @default.
• W2974058425 cites W1988566322 @default.
• W2974058425 cites W2012315687 @default.
• W2974058425 cites W2021687900 @default.
• W2974058425 cites W2024733066 @default.
• W2974058425 cites W2038981426 @default.
• W2974058425 cites W2055769770 @default.
• W2974058425 cites W2057397568 @default.
• W2974058425 cites W2084867000 @default.
• W2974058425 cites W2093071489 @default.
• W2974058425 cites W2097578379 @default.
• W2974058425 cites W2115221614 @default.
• W2974058425 cites W2125468958 @default.
• W2974058425 cites W2127875452 @default.
• W2974058425 cites W2141713511 @default.
• W2974058425 cites W2146506439 @default.
• W2974058425 cites W2155965977 @default.
• W2974058425 cites W2158666727 @default.
• W2974058425 cites W2167639134 @default.
• W2974058425 cites W2171294019 @default.
• W2974058425 cites W2188846692 @default.
• W2974058425 cites W2264767503 @default.
• W2974058425 cites W2337454357 @default.
• W2974058425 cites W2412612879 @default.
• W2974058425 cites W2570191103 @default.
• W2974058425 cites W2591855637 @default.
• W2974058425 cites W2607457744 @default.
• W2974058425 cites W4239837977 @default.
• W2974058425 cites W612972800 @default.
• W2974058425 doi "https://doi.org/10.1001/jama.2019.13206" @default.
• W2974058425 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6753652" @default.
• W2974058425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31536102" @default.
• W2974058425 hasPublicationYear "2019" @default.
• W2974058425 type Work @default.
• W2974058425 sameAs 2974058425 @default.
• W2974058425 citedByCount "44" @default.
• W2974058425 countsByYear W29740584252020 @default.
• W2974058425 countsByYear W29740584252021 @default.
• W2974058425 countsByYear W29740584252022 @default.
• W2974058425 countsByYear W29740584252023 @default.
• W2974058425 crossrefType "journal-article" @default.
• W2974058425 hasAuthorship W2974058425A5000770289 @default.
• W2974058425 hasAuthorship W2974058425A5016472568 @default.
• W2974058425 hasAuthorship W2974058425A5020436097 @default.
• W2974058425 hasAuthorship W2974058425A5032249344 @default.
• W2974058425 hasAuthorship W2974058425A5048334353 @default.
• W2974058425 hasAuthorship W2974058425A5057987348 @default.
• W2974058425 hasAuthorship W2974058425A5063398179 @default.
• W2974058425 hasAuthorship W2974058425A5086894012 @default.
• W2974058425 hasAuthorship W2974058425A5089308976 @default.
• W2974058425 hasBestOaLocation W29740584251 @default.
• W2974058425 hasConcept C119060515 @default.
• W2974058425 hasConcept C126322002 @default.
• W2974058425 hasConcept C134018914 @default.
• W2974058425 hasConcept C159641895 @default.
• W2974058425 hasConcept C167135981 @default.
• W2974058425 hasConcept C207103383 @default.
• W2974058425 hasConcept C2777180221 @default.
• W2974058425 hasConcept C2778854520 @default.
• W2974058425 hasConcept C2779306644 @default.
• W2974058425 hasConcept C2780323712 @default.
• W2974058425 hasConcept C2780400711 @default.
• W2974058425 hasConcept C2780739214 @default.
• W2974058425 hasConcept C44249647 @default.
• W2974058425 hasConcept C500558357 @default.
• W2974058425 hasConcept C555293320 @default.
• W2974058425 hasConcept C71924100 @default.
• W2974058425 hasConceptScore W2974058425C119060515 @default.
• W2974058425 hasConceptScore W2974058425C126322002 @default.
• W2974058425 hasConceptScore W2974058425C134018914 @default.
• W2974058425 hasConceptScore W2974058425C159641895 @default.
• W2974058425 hasConceptScore W2974058425C167135981 @default.
• W2974058425 hasConceptScore W2974058425C207103383 @default.
• W2974058425 hasConceptScore W2974058425C2777180221 @default.
• W2974058425 hasConceptScore W2974058425C2778854520 @default.
• W2974058425 hasConceptScore W2974058425C2779306644 @default.
• W2974058425 hasConceptScore W2974058425C2780323712 @default.
• W2974058425 hasConceptScore W2974058425C2780400711 @default.
• W2974058425 hasConceptScore W2974058425C2780739214 @default.
• W2974058425 hasConceptScore W2974058425C44249647 @default.

• next